Aisling raises $650 million for new fund
This article was originally published in Scrip
The private equity firm Aisling Capital has raised $650 million for a new life sciences fund, Aisling Capital III. The New York-based company will invest primarily in companies developing pharmaceutical, biopharmaceutical and medical products, but also in those that provide drug development, manufacturing and other services to the pharmaceutical industry. One of Aisling's investor companies, Map Pharmaceuticals, signed a $900 million co-development and commercialisation deal with AstraZeneca last month for Map's unit dose budesonide (Scrip Online, December 22nd, 2008).
You may also be interested in...
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.